Interaction of cytosine arabinoside and lovastatin in human leukemia cells

Sarah A. Holstein, Raymond J. Hohl

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Cytosine arabinoside (ara-C) is widely used for the treatment of leukemias and displays significant toxicities. Lovastatin, an HMG-CoA reductase inhibitor, is extensively used to treat hypercholesterolemia. To determine whether lovastatin could augment ara-C's activity we have examined their effects in the human erythroleukemia K562 cell line and the ara-C resistant ARAC8D cell line. A synergistic interaction between the two drugs was found. We have demonstrated that the interaction does not occur at the level of RAS but may involve lovastatin's effect of downregulating MAPK activity and preventing ara-C-induced MAPK activation. These studies represent the first description of a potentially beneficial interaction between lovastatin and ara-C that could be applied to the treatment of human leukemia.

Original languageEnglish (US)
Pages (from-to)651-660
Number of pages10
JournalLeukemia Research
Volume25
Issue number8
DOIs
StatePublished - Jun 11 2001

Fingerprint

Lovastatin
Cytarabine
Leukemia
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cell Line
Leukemia, Erythroblastic, Acute
K562 Cells
Hypercholesterolemia
Down-Regulation
Pharmaceutical Preparations

Keywords

  • Apoptosis
  • Cytosine arabinoside
  • HMG-CoA reductase
  • MAPK
  • RAS

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Interaction of cytosine arabinoside and lovastatin in human leukemia cells. / Holstein, Sarah A.; Hohl, Raymond J.

In: Leukemia Research, Vol. 25, No. 8, 11.06.2001, p. 651-660.

Research output: Contribution to journalArticle

@article{d632fc515e7d4ffb9297fc3525b9c4d2,
title = "Interaction of cytosine arabinoside and lovastatin in human leukemia cells",
abstract = "Cytosine arabinoside (ara-C) is widely used for the treatment of leukemias and displays significant toxicities. Lovastatin, an HMG-CoA reductase inhibitor, is extensively used to treat hypercholesterolemia. To determine whether lovastatin could augment ara-C's activity we have examined their effects in the human erythroleukemia K562 cell line and the ara-C resistant ARAC8D cell line. A synergistic interaction between the two drugs was found. We have demonstrated that the interaction does not occur at the level of RAS but may involve lovastatin's effect of downregulating MAPK activity and preventing ara-C-induced MAPK activation. These studies represent the first description of a potentially beneficial interaction between lovastatin and ara-C that could be applied to the treatment of human leukemia.",
keywords = "Apoptosis, Cytosine arabinoside, HMG-CoA reductase, MAPK, RAS",
author = "Holstein, {Sarah A.} and Hohl, {Raymond J.}",
year = "2001",
month = "6",
day = "11",
doi = "10.1016/S0145-2126(00)00162-4",
language = "English (US)",
volume = "25",
pages = "651--660",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Interaction of cytosine arabinoside and lovastatin in human leukemia cells

AU - Holstein, Sarah A.

AU - Hohl, Raymond J.

PY - 2001/6/11

Y1 - 2001/6/11

N2 - Cytosine arabinoside (ara-C) is widely used for the treatment of leukemias and displays significant toxicities. Lovastatin, an HMG-CoA reductase inhibitor, is extensively used to treat hypercholesterolemia. To determine whether lovastatin could augment ara-C's activity we have examined their effects in the human erythroleukemia K562 cell line and the ara-C resistant ARAC8D cell line. A synergistic interaction between the two drugs was found. We have demonstrated that the interaction does not occur at the level of RAS but may involve lovastatin's effect of downregulating MAPK activity and preventing ara-C-induced MAPK activation. These studies represent the first description of a potentially beneficial interaction between lovastatin and ara-C that could be applied to the treatment of human leukemia.

AB - Cytosine arabinoside (ara-C) is widely used for the treatment of leukemias and displays significant toxicities. Lovastatin, an HMG-CoA reductase inhibitor, is extensively used to treat hypercholesterolemia. To determine whether lovastatin could augment ara-C's activity we have examined their effects in the human erythroleukemia K562 cell line and the ara-C resistant ARAC8D cell line. A synergistic interaction between the two drugs was found. We have demonstrated that the interaction does not occur at the level of RAS but may involve lovastatin's effect of downregulating MAPK activity and preventing ara-C-induced MAPK activation. These studies represent the first description of a potentially beneficial interaction between lovastatin and ara-C that could be applied to the treatment of human leukemia.

KW - Apoptosis

KW - Cytosine arabinoside

KW - HMG-CoA reductase

KW - MAPK

KW - RAS

UR - http://www.scopus.com/inward/record.url?scp=0035020378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035020378&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(00)00162-4

DO - 10.1016/S0145-2126(00)00162-4

M3 - Article

C2 - 11397469

AN - SCOPUS:0035020378

VL - 25

SP - 651

EP - 660

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -